Utah Medical Products, Inc.

As of July 7, 2025, Utah Medical Products, Inc. is considered undervalued with attractive valuation metrics, despite recent stock performance lagging behind the S&P 500, indicating a potential investment opportunity.

As of June 17, 2025, Utah Medical Products, Inc. is in a bearish trend with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals from the MACD and KST.

As of January 29, 2024, Utah Medical Products, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 14, an EV to EBITDA of 6.29, and a strong ROCE of 38.15%, making it competitively priced against peers despite a year-to-date stock performance lagging behind the S&P 500.

As of March 2022, the management team of Utah Medical Products, Inc. includes Kevin Cornwell (Chairman, President, CEO, Secretary), Ernst Hoyer (Lead Independent Director), Paul Richins (Director), Dr. James Beeson (Independent Director), and Dr. Barbara Payne (Independent Director).

Utah Medical Products, Inc. manufactures disposable medical devices for hospitals and is classified as a micro-cap company with a market cap of $175.34 million. As of March 2025, it reported net sales of $10 million and a net profit of $3 million.

As of Jun 18, Utah Medical Products, Inc. has a market capitalization of 175.34 million, with net sales of 39.28 million and a net profit of 12.95 million over the latest four quarters.